Last reviewed · How we verify
Bromhexine and Spironolactone
Bromhexine acts as a mucolytic agent to thin respiratory secretions while spironolactone is a potassium-sparing diuretic and aldosterone antagonist.
Bromhexine acts as a mucolytic agent to thin respiratory secretions while spironolactone is a potassium-sparing diuretic and aldosterone antagonist. Used for Respiratory conditions with excessive mucus production (bromhexine component), Fluid retention or hypertension (spironolactone component).
At a glance
| Generic name | Bromhexine and Spironolactone |
|---|---|
| Sponsor | Lomonosov Moscow State University Medical Research and Educational Center |
| Drug class | Mucolytic agent combined with potassium-sparing diuretic/aldosterone antagonist |
| Target | Mucopolysaccharide degradation (bromhexine); mineralocorticoid receptor (spironolactone) |
| Modality | Small molecule |
| Therapeutic area | Respiratory and Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Bromhexine breaks down mucopolysaccharides in sputum to reduce mucus viscosity and improve clearance, while spironolactone blocks aldosterone receptors in the collecting duct to promote sodium and water excretion while retaining potassium. This combination may be investigated for conditions involving both respiratory secretion management and fluid/electrolyte balance, though the rationale for combining these agents in a single formulation is uncommon.
Approved indications
- Respiratory conditions with excessive mucus production (bromhexine component)
- Fluid retention or hypertension (spironolactone component)
Common side effects
- Gastrointestinal disturbance
- Hyperkalemia
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: